Trial Profile
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Mar 2024
Price :
$35
*
At a glance
- Drugs Elasomeran (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms COVE
- Sponsors Moderna Therapeutics
- 23 Jun 2023 Results from four (NCT04470427, NCT04516746, NCT04505722, and NCT04611802) COVID-19 prevention network efficacy trials published in the Vaccine
- 11 Jan 2023 Status changed from active, no longer recruiting to completed.
- 20 Sep 2022 Results of pooled analysis (n=1671) assessing the association between immunogenicity and reactogenicity after two mRNA-1273 (100 µg) injections published in the Clinical Infectious Diseases